3-chloro-6-(4-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine | 1116743-29-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-chloro-6-(4-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine
• 英文别名: 3-Chloro-6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine
• CAS: 1116743-29-3
• 化学式: C₁₁H₆ClFN₄
• 分子量: 248.647
• InChiKey: UFYSEIRQWVNZCO-UHFFFAOYSA-N

物化性质

• 密度：
  1.54±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  3-chloro-6-(4-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine 在 锌 methanol-dichloromethane 作用下， 以 溶剂黄146 为溶剂， 反应 1.0h， 以263 mg of 3-chloro-6-(4-fluorophenyl)-7,8-dihydro[1,2,4]triazolo[4,3-b]pyridazine are thus obtained in the form of a yellowy-brown powder的产率得到3-chloro-6-(4-fluorophenyl)-7,8-dihydro[1,2,4]triazolo[4,3-b]pyridazine
  参考文献：
  名称：

  6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors

  摘要：

  本公开涉及化合物的公式(I)：其中，A、W、X和Ra如本公开所定义，以及其盐，以及包含所述化合物的制药组合物，制备它们的过程，以及它们作为药物的用途，特别是作为MET抑制剂。

  公开号：

  US09115134B2
• 作为产物：
  描述：

  6-(4-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazin-3-ol 在 三氯氧磷 、 碳酸氢钠 作用下， 以 水 为溶剂， 反应 1.0h， 生成 3-chloro-6-(4-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine
  参考文献：
  名称：

  NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMNACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS

  摘要：

  该公开涉及式(I)的化合物： 其中 ，A、W、X和Ra如公开所定义，并其盐，以及包含所述化合物的药物组合物，用于制备它们的方法，以及它们作为药物的用途，特别是作为MET抑制剂。

  公开号：

  US20100298315A1
• 作为试剂：
  描述：

  3-chloro-6-(4-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine 、 1-(2-morpholin-4-ylethyl)-3-(6-sulphanyl-1,3-benzothiazol-2-yl)urea 在 3-chloro-6-(4-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine 作用下， 以22的产率得到肌氨酰125844
  参考文献：
  名称：

  J. Med. Chem. 2016, 59, 7066-7074

  摘要：

  DOI：

文献信息

• DERIVATIVES OF 6-(6-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) 5-FLUORO BENZOTHIAZOLES AND 5-FLUORO BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS
  申请人：Nemecek Conception

  公开号：US20120165326A1

  公开（公告）日：2012-06-28

  The invention relates to novel products of the formula (I) where: (II) is a single or double bond; F is a fluorine atom, Ra is H, HaI, alkoxy, O-cycloalkyl, —O— heterocycloalkyl; —NH-heterocycloalkyl, heteroaryl, phenyl, NHCOalk NHCOcycloalk or NR1 R2; X is S, SO or SO2, A is NH or S; W is H, alkyl, or COR with R being cycloalkyl; alkyl optionally substituted by NR3R4, alkoxy, hydroxy, phenyl, heteroaryl or heterocycloalkyl; alkoxy optionally substituted by NR3R4, i.e. a O—(CH2)n-NR3R4 radical, an O-phenyl or an O—(CH2)n-phenyl radical, with phenyl optionally substituted and n=1 to 4; or the NR1 R2 radical; R1 is H or alk and R2 is H, cycloalkyl or alkyl; R3 and R4 are H, alk, cycloalkyl, heteroaryl or phenyl; R1, R2 and/or R3, R4 form a cycle together with N optionally containing O, S, N and/or NH; heterocycloalkyl, heteroaryl and phenyl and cycles all being optionally substituted; wherein said products can be in any isomer or salt form, and can be used as drugs, in particular as MET inhibitors.

  该发明涉及公式(I)的新产品，其中：(II)是单键或双键；F是氟原子，Ra是H，HaI，烷氧基，O-环烷基，—O—杂环烷基；—NH-杂环烷基，杂芳基，苯基，NHCO烷基，NHCO环烷基或NR1R2；X是S，SO或SO2，A是NH或S；W是H，烷基，或COR，其中R是环烷基；烷基可选择地被NR3R4，烷氧基，羟基，苯基，杂芳基或杂环烷基取代；烷氧基可选择地被NR3R4取代，即O—(CH2)n-NR3R4基团，O-苯基或O—(CH2)n-苯基基团，其中苯基可选择地被取代，n=1至4；或NR1R2基团；R1是H或烷基，R2是H，环烷基或烷基；R3和R4是H，烷基，环烷基，杂芳基或苯基；R1，R2和/或R3，R4与N一起形成一个环，该环可选择地含有O，S，N和/或NH；杂环烷基，杂芳基和苯基以及环均可选择地被取代；所述产品可以是任何异构体或盐形式，并可用作药物，特别是MET抑制剂。
• NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS
  申请人：Albert Eva

  公开号：US20140005189A1

  公开（公告）日：2014-01-02

  The disclosure relates to compounds of formula (I): wherein , A, W, X, and Ra are as defined in the disclosure, and salts thereof, and to pharmaceutical compositions comprising said compounds, to processes for preparing them, and to their use as medicaments, in particular as MET inhibitors.

  本公开涉及式(I)的化合物：其中，A、W、X和Ra如本公开所定义的那样，以及其盐，以及包含所述化合物的制药组合物，制备它们的过程，以及它们作为药物的用途，特别是作为MET抑制剂的用途。
• Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844)
  作者：Antonio Ugolini、Mireille Kenigsberg、Alexey Rak、Francois Vallée、Jacques Houtmann、Maryse Lowinski、Cécile Capdevila、Jean Khider、Eva Albert、Nathalie Martinet、Conception Nemecek、Sandrine Grapinet、Eric Bacqué、Manfred Roesner、Christine Delaisi、Loreley Calvet、Fabrice Bonche、Dorothée Semiond、Coumaran Egile、Hélène Goulaouic、Laurent Schio

  DOI：10.1021/acs.jmedchem.6b00280

  日期：2016.8.11

  The HGF/MET pathway is frequently activated in a variety of cancer types. Several selective small molecule inhibitors of the MET kinase are currently in clinical evaluation, in particular for NSCLC, liver, and gastric cancer patients. We report herein the discovery of a series of triazolopyridazines that are selective inhibitors of wild-type (WT) MET kinase and several clinically relevant mutants. We provide insight into their mode of binding and report unprecedented crystal structures of the Y1230H variant. A multiparametric chemical optimization approach allowed the identification of compound 12 (SAR125844) as a development candidate. In this chemical series, absence of CYP3A4 inhibition was obtained at the expense of satisfactory oral absorption. Compound 12, a promising parenteral agent for the treatment of MET-dependent cancers, promoted sustained target engagement at tolerated doses in a human xenograft tumor model. Preclinical pharmacokinetics conducted in several species were predictive for the observed pharmacokinetic behavior of 12 in cancer patients.
• NOUVEAUX DERIVES DE 6-TRIAZOLOPYRIDAZINE-SULFANYL BENZOTHIAZOLE ET BENZIMIDAZOLE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
  申请人：SANOFI

  公开号：EP2178881B1

  公开（公告）日：2013-10-02
• DERIVES DE 6-(6-SUBSTITUE-TRIAZOLOPYRIDAZINE-SULFANYL) 5-FLUORO-BENZOTHIAZOLES ET 5-FLUORO-BENZIMIDAZOLES : PREPARATION, APPLICATION COMME MEDICAMENTS ET UTILISATION COMME INHIBITEURS DE MET
  申请人：SANOFI

  公开号：EP2393793A1

  公开（公告）日：2011-12-14